The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus

Antiviral Research

Volumn 125, Issue , 2016, Pages 71-78

  McMullan, Laura K ^a   Flint, Mike ^a   Dyall, Julie ^b   Albariño, César ^a   Olinger, Gene G ^b   Foster, Scott ^c   Sethna, Phiroze ^c   Hensley, Lisa E ^b   Nichol, Stuart T ^a   Lanier, E Randall ^c   Spiropoulou, Christina F ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Chimerix   (United States)

Author keywords

Antiviral therapy; Brincidofovir; Ebola; In vitro screen

Indexed keywords

3 HEXADECYLOXY 1 PROPANOL; BRINCIDOFOVIR; CIDOFOVIR; LIPID; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DOUBLE-STRANDED DNA VIRUS; EBOLAVIRUS; EC50; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RNA VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; HELA CELL LINE; HEMORRHAGIC FEVER, EBOLA; MALE; PRECLINICAL STUDY; PROCEDURES; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VERO CELL LINE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CYTOSINE; DRUG EVALUATION, PRECLINICAL; EBOLAVIRUS; HELA CELLS; HEMORRHAGIC FEVER, EBOLA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPIDS; MALE; ORGANOPHOSPHONATES; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS; VIRUS REPLICATION;

EID: 84949504134     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.10.010     Document Type: Article

References (22)

1. D.F. Florescu, A.C. Kalil, A.L. Hewlett, A.J. Schuh, U. Stroher, T.M. Uyeki, and P.W. Smith Administration of brincidofovir and convalescent plasma in a patient with ebola virus disease Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 61 2015 969 973
2. K.Y. Hostetler Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate Viruses 2 2010 2213 2225
3. R. Lanier, L. Trost, T. Tippin, B. Lampert, A. Robertson, S. Foster, M. Rose, W. Painter, R. O'Mahony, M. Almond, and G. Painter Development of CMX001 for the treatment of poxvirus infections Viruses 2 2010 2740 2762
4. S. Lanini, A. Zumla, J.P. Ioannidis, A. Di Caro, S. Krishna, L. Gostin, E. Girardi, M. Pletschette, G. Strada, A. Baritussio, G. Portella, G. Apolone, S. Cavuto, R. Satolli, P. Kremsner, F. Vairo, and G. Ippolito Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? The Lancet Infect. Dis. 15 2015 738 745
5. A.M. Liddell, R.T. Davey Jr., A.K. Mehta, J.B. Varkey, C.S. Kraft, G.K. Tseggay, O. Badidi, A.C. Faust, K.V. Brown, A.F. Suffredini, K. Barrett, M.J. Wolcott, V.C. Marconi, G.M. Lyon III, G.L. Weinstein, K. Weinmeister, S. Sutton, M. Hazbun, C.G. Albarino, Z. Reed, D. Cannon, U. Stroher, M. Feldman, B.S. Ribner, H.C. Lane, A.S. Fauci, and T.M. Uyeki Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States Ann. Intern. Med. 163 2015 81 90
6. W.C. Magee, K.Y. Hostetler, and D.H. Evans Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate Antimicrob. Agents Chemother. 49 2005 3153 3162
7. M.E. Miller, S. Adhikary, A.A. Kolokoltsov, and R.A. Davey Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection J. Virol. 86 2012 7473 7483
8. E.L. Mohr, L.K. McMullan, M.K. Lo, J.R. Spengler, E. Bergeron, C.G. Albarino, P. Shrivastava-Ranjan, C.F. Chiang, S.T. Nichol, C.F. Spiropoulou, and M. Flint Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses Antivir. Res. 120 2015 40 47
9. L. Oestereich, A. Ludtke, S. Wurr, T. Rieger, C. Munoz-Fontela, and S. Gunther Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model Antivir. Res. 105 2014 17 21
10. L.J. Reed, and H. Muench A simple method of estimating fifty per cent endpoints Am. J. Hyg. 27 1938 493 497
11. D. Sissoko, E. Folkesson, M. Abdoul, A.H. Beavogui, S. Gunther, S. Shepherd, C. Danel, F. Mentre, X. Anglaret, and D. Malvy Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI Trial in Guinea, CROI, Seattle, Washington, USA 2015
12. S.J. Smither, L.S. Eastaugh, J.A. Steward, M. Nelson, R.P. Lenk, and M.S. Lever Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model Antivir. Res. 104 2014 153 155
13. J.S. Towner, J. Paragas, J.E. Dover, M. Gupta, C.S. Goldsmith, J.W. Huggins, and S.T. Nichol Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening Virology 332 2005 20 27
14. L.S. Uebelhoer, C.G. Albarino, L.K. McMullan, A.K. Chakrabarti, J.P. Vincent, S.T. Nichol, and J.S. Towner High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses Antivir. Res. 106 2014 86 94
15. WHO Ebola Virus Disease Update - West Africa 2014 http://www.who.int/csr/don/2014-08-08-ebola/en/
16. WHO Categorization and Prioritization of Drugs for Consideration for Testing or Use in Patients Infected with Ebola 2015 http://www.who.int/medicines/ebola-treatment/2015-0703TablesofEbolaDrugs.pdf?ua=1
17. WHO Ebola Situation Reports 2015 http://apps.who.int/ebola/ebola-situation-reports
18. WHO Emergency Use Assessment and Listing Procedure (EUAL) for Candidate Medicines for Use in the Context of a Public Health Emergency 2015 http://www.who.int/medicines/news/EUAL-medicines-7July2015-MS.pdf?ua=1
19. G. Wong, and G.P. Kobinger Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak Clin. Microbiol. Rev. 28 2015 593 601
20. X. Xiong, J.L. Smith, and M.S. Chen Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation Antimicrob. Agents Chemother. 41 1997 594 599
21. X. Xiong, J.L. Smith, C. Kim, E.S. Huang, and M.S. Chen Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase Biochem. Pharmacol. 51 1996 1563 1567
22. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73